What's breaking now, across thousands of outlets.
The latest news from CMS, HHS and more across Washington, D.C.
We haven't written up this one. Fierce Healthcare has the full story — the link below goes straight to it.
Curium has set the list price for Bexlutry, its radiosimilar to Novartis’ Lutathera, at $63,524 per infusion — about a 5% discount to the cost of the pharma giant’s drug.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common liver condition that can follow very different paths among patients.
Vaccination not only prevents disease caused by acute infection but also protects against long-term immune-related sequelae that can follow an acute viral infection.
Judith Lucy's breast cancer diagnosis means she has joined a club nobody wants to be a part of. A survivor tells how humour and resilience can make the journey easier.
Semi-annual redeterminations and work requirements will test payer-mix assumptions across the industry over the next two years.
(MedPage Today) -- After years of inactivity, therapeutic development for dermatomyositis has begun to move forward with several new therapies and therapeutic strategies.
